Fundraising FoxRTW Investments L.P. — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Aquestive Therapeutics develops and commercializes oral film drug formulations and other novel delivery systems for treatments in neurology, psychiatry, and emergency care, operating manufacturing facilities in Indiana that produce both licensed pharmaceutical products and proprietary candidates for regulated markets including the U.S., EU, and Australia.
BiotechWarren, US
Keith J Kendall(Chief Executive Officer)inA. Mark Shobel(Chief Operating Officer)Theresa Wood(Vice President, Human Resources)inPeter Boyd(Vice President, Value Delivery)Daniel Barber(Vice President, Business and Product Development)inJohn T Maxwell(Chief Financial Officer, Treasurer, Secretary)in
Co-investorsOaktree
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM Healthcare InvestmentsHBM PartnersBiotechnology Value FundBlackRockForbion+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Small MoleculesYarrow
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.